论文信息 - Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results. - 字舞流文

Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.

H. Nishiyama | V. Master | N. Vasdev | B. Tran | J. Catto | S. Daneshmand | G. Pignot | M. Rouprêt | Y. Loriot | A. Tubaro | N. Shimizu | Y. Miura | M. Baig | J. Redorta | S. Triantos | V. Naini | Gary D. Steinberg | Jürgen E. Gschwend | Lauren Crow